Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland

Journal of Infectious Diseases

Volumn 177, Issue 3, 1998, Pages 683-691

  Perkins, B A ^a   Jonsdottir, K ^c   Briem, H ^c   Griffiths, E ^b   Plikaytis, B D ^c   Hoiby, E A ^c   Rosenqvist, E ^c   Holst, J ^c   Nokleby, H ^c   Sotolongo, F ^c   Sierra, G ^c   Campa, H C ^c   Carlone, G M ^c   Williams, D ^c   Dykes, J ^c   Kapczynski, D ^c   Tikhomirov, E ^c   Wenger, J D ^b   Broome, C V ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; ICELAND; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SERUM BACTERICIDAL ACTIVITY;

EID: 17344371261     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514232     Document Type: Article

References (17)

1. Sierra GVG, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991;14:195-207.
2. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of an outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338:1093-6.
3. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus IV. Immunogenicity of the group A and group C polysaccharides in human volunteers. J Exp Med 1969;129:1367-84.
4. Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal vaccine group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 1995;13:821-9.
5. Moraes JC, Perkins BA, Camargo MCC, et al. Protective efficacy of a serogroup B meningococcal vaccine in São Paulo, Brazil. Lancet 1992;340:1074-8.
6. Milagres LG, Ramos SR, Sacchi CT, et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 1994;62:4419-24.
7. Rosenqvist E, Hoiby EA, Wedege E, et al. Human antibody response to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995;63:4642-52.
8. Reeves MW, Perkins BA, Diermeyer M, Wenger JD. Epidemic-associated Neisseria meningitidis detected by multilocus enzyme electrophoresis. Emerging Infect Dis 1995;1:53-4.
9. Wedege E, Hoiby EA, Rosenqvist E, Froholm LO. Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting and ELISA. J Med Microbiol 1990;31:195-201.
10. Hoiby EA, Rosenqvist E, Froholm LO, et al. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann 1991;14:147-56.
11. Rosenqvist E, Hoiby EA, Bjune G, et al. Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies. NIPH Ann 1991;14:169-81.
12. Bjune G, Gronnesby JK, Hoiby EA, Closs O, Nokleby H. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann 1991;14:125-32.
13. van der Ley P, van der Biezen J, Poolman JT. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the por A gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 1995;13:401-7.
14. Aase A, Bjune G, Hoiby EA, Rosenqvist E, Pedersen AK, Michaelsen TE. Comparison of opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect Immun 1995;63:3531-6.
15. Saukkonen K, Leinonen M, Kayhty H, Abdillahi H, Poolman JT. Monoclonal antibodies to the rough lipopolysaccharide of Neisseria meningitidis protect infant rats from meningococcal infection. J Infect Dis 1988;158:209-12.
16. Pan American Health Organization. Immunogenicity and reactogenicity of two outer membrane protein - based anti-meningococcal vaccines in Santiago, Chile (meeting report). Washington, DC: PAHO, 1995.
17. Tappero J, Lagos R, Maldonado A, et al. Serum bactericidal activity elicited by two outer membrane serogroup B meningococcal vaccines among infants, pre-school children, and adults in Santiago, Chile. In: Proceedings of the 10th International Pathogenic Neisseria Conference (Baltimore). Bethesda, MD: National Institutes of Health, 1996.